3Neuwirtová R,Mociková K,Jelinek J. Mixed myelodysplastic and myeloproliferative syndromes[J].Casopis Lekaru Ceskych,1997.724-729.
4Marisavljevic D,Cemerikic V,Rolovic Z. Hypocellular myelodysplastic syndromes:clinical and biological significance[J].Medical Oncology,2005.169-175.
5Kristensen JS,Hokland P. Monoclonal antibody ratios in malignant Myeloid dieases:diagnostic and prognostic use in myelodysplastic syndromes[J].British Journal of Haematology,1990.270-276.
6Ogata K,Nakamura K,Yokose N. Clinical significance of phenotypic features of blasts in patiens with myelodysplastic syndrome[J].Blood,2002.3887-3896.
7Baxter EJ,Scott LM,Campbell PJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[J].Lancet,2005.1054-1061.
8Kralovics R,Passamonti F,Buser AS. A gain-of-function mutation of JAK2 in myeloproliferative disorders[J].New England Journal of Medicine,2005.1779-1790.
9Levine RL,Wadleigh M,Cools J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera,essential thrombocythemia,and myeloid metaplasia with myelofibrosis[J].Cancer Cells,2005.387-397.
10James C,Ugo V,Le Couedic JP. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera[J].Nature,2005.1144-1148.
